ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of ProKidney Corp. (NASDAQ:PROK) have been given an average rating of “Moderate Buy” by the eight analysts that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $7.40.

PROK has been the topic of several research analyst reports. HC Wainwright assumed coverage on ProKidney in a research note on Tuesday, December 16th. They issued a “buy” rating and a $12.00 price objective on the stock. Jefferies Financial Group raised ProKidney to a “strong-buy” rating in a research report on Wednesday. Wall Street Zen lowered ProKidney from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a research report on Thursday, January 22nd.

Institutional Investors Weigh In On ProKidney

Several institutional investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers bought a new position in ProKidney during the fourth quarter worth about $28,000. Zullo Investment Group Inc. bought a new stake in shares of ProKidney in the third quarter valued at approximately $28,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of ProKidney in the second quarter valued at approximately $36,000. AQR Capital Management LLC lifted its stake in shares of ProKidney by 106.4% during the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock valued at $46,000 after buying an additional 27,098 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in shares of ProKidney during the 4th quarter valued at approximately $65,000. 51.59% of the stock is owned by hedge funds and other institutional investors.

ProKidney Stock Performance

Shares of PROK stock opened at $1.93 on Friday. The firm has a market cap of $580.60 million, a price-to-earnings ratio of -3.71 and a beta of 1.75. ProKidney has a 52 week low of $0.46 and a 52 week high of $7.13. The firm’s 50-day simple moving average is $2.15 and its two-hundred day simple moving average is $2.42.

ProKidney (NASDAQ:PROK) last released its earnings results on Wednesday, March 18th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.00 million. Analysts forecast that ProKidney will post -0.57 earnings per share for the current year.

Trending Headlines about ProKidney

Here are the key news stories impacting ProKidney this week:

• Positive Sentiment: Jefferies upgraded the stock, providing investor support that can buoy sentiment and trading interest. ProKidney (NASDAQ:PROK) Upgraded at Jefferies Financial Group
• Positive Sentiment: ProKidney reported a narrowed loss and highlighted an upcoming pivotal kidney‑treatment trial — a near‑term binary clinical catalyst that could drive upside if results are favorable. ProKidney narrows loss to $150M as it eyes crucial kidney treatment trial results
• Neutral Sentiment: HC Wainwright reiterated a “Buy” rating and a $12 price target, which is supportive, but the firm also released updated quarterly and multi‑year EPS models for PROK (showing expected losses through 2029 before eventual positive FP2030 guidance). This keeps a bullish analyst voice in the market while signalling longer cash‑burn expectations. HC Wainwright estimates and price target (MarketBeat)
• Negative Sentiment: HC Wainwright cut several FY2026–FY2029 EPS estimates (small downgrades to loss per share forecasts), which can dampen valuation upside and raise concerns about the company’s near‑term operating trajectory. HC Wainwright lowers FY estimates (MarketBeat)
• Negative Sentiment: Wall Street Zen lowered its rating on PROK, adding short‑term negative pressure from another sell‑side view. ProKidney (NASDAQ:PROK) Stock Rating Lowered by Wall Street Zen
• Negative Sentiment: TipRanks flagged new trade‑policy and export/regulatory risks to ProKidney’s supply chain and financial stability, a company‑disclosed risk that can increase execution uncertainty for investors. Trade Policy Risks (TipRanks)

ProKidney Company Profile

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.